Halobetasol Propionate, Tazarotene Combo Therapy Tested to Treat Psoriasis Symptoms



Researchers found that a topical therapy that combined halobetasol propionate 0.01% with tazarotene 0.045% (HP/TAZ) lotion effectively reduced the symptoms of psoriasis.

The multicenter, randomized, double-blind, vehicle-controlled phase 2 study included 212 participants with moderate-to-severe psoriasis. Participants applied either combination HP/TAZ lotion, active HP lotion or TAZ lotion, or vehicle once a day for 8 weeks and were followed for 4 weeks after treatment. Treatment success was defined as at least a 2-grade improvement on the Investigator’s Global Assessment score from baseline and “clear” or “almost clear skin.” In addition, the researchers assessed the effect of treatment on psoriasis symptoms, including erythema, plaque elevation, and scaling of the targeted lesion.

Impact of Biologics on Coronary Plaque in Psoriasis Patients Investigated
Do Vitamin D Levels Affect Psoriasis Severity?
Do Interleukin Inhibitors Affect Bodyweight?

Overall, 38.2% of participants who received HP/TAZ experienced treatment success compared with 21% who received only HP, 12.8% who received only TAZ, and 6.9% who received vehicle. HP/TAZ lotion was superior at maintaining reductions in erythema, plaque elevation, and scaling of targeted lesions. On assessments of erythema, plaque elevation, and scaling, 49.1%, 54.5%, 54.5%, respectively, of participants experienced treatment successes compared with 38.7%, 48.4%, and 48.4% of those treated with HP; 29.8%, 31.9%, and 23.4% of those with TAZ; and 13.8%, 20.7%, and 20.7% of those treated with vehicle.

Adverse effects observed in the study were minimal and often resolved during the posttreatment period.

“In conclusion, HP 0.01%/TAZ 0.045% lotion provides synergistic efficacy following 8 weeks of therapy that is sustained after a 4-week posttreatment period,” the researchers concluded. 


Pariser DM, Green LJ, Gold LS, Sugarman JL, Lin T, Pillai R. Halobetasol 0.01%/tazarotene 0.045% lotion in the treatment of moderate-to-severe plaque psoriasis: maintenance of therapeutic effect after cessation of therapy. J Drugs Dermatol. 2018;17(7):723-726.